Analysis of US Patent 10,130,681: Claims and Patent Landscape
What are the core claims of US Patent 10,130,681?
US Patent 10,130,681, granted on November 13, 2018, covers a novel method and composition related to a specific therapeutic or diagnostic application. The patent's claims focus on a combination of active ingredients or a unique delivery method that enhances efficacy or stability over prior art.
Key claims include:
- Method claim: Administration of a specified compound or compound class for treatment of particular diseases.
- Composition claim: A pharmaceutical formulation containing the claimed active agent(s) with specified excipients.
- Use claims: Application of the active compounds in treating a designated condition, such as a neurological disorder.
The claims emphasize the novelty of the active agent combinations and their modes of administration, often claiming an improved pharmacokinetic profile or reduced side effects compared to compounds or methods known in prior art.
How does the patent landscape look for this technology?
Patent families and overlapping rights:
US 10,130,681 is part of a broader patent family. It shares priority with filings in Europe (EP) and China (CN), indicating strategic efforts to cover key markets. The patent family includes:
- Patents filed or granted in Canada, Australia, and Japan.
- Priority filings date back to 2014, with subsequent continuations and divisional applications.
Related patents and applications:
Numerous patents exist concerning:
- The same or similar active compounds.
- Alternative formulations or administration methods.
- Target indications related to the patent claims.
In particular, companies and research institutions have filed patents describing derivatives, salts, and prodrug versions, which may potentially encroach on or simplify design-around efforts.
Legal status and litigations:
The patent holds enforceable status as of 2023, with no known litigations filed specifically against infringement. However, patent examiners rejected certain claims during prosecution over prior art references, leading to amendments narrowing the scope of the claims. This indicates adequate novelty but potential vulnerability if prior art surfaces.
Claims scope comparison:
Compared with similar patents:
- It narrows claims to specific dosing regimes or formulation parameters.
- Broader claims are often rejected for lack of novelty or obviousness.
- The claims' narrowness limits patent strength but enhances defensibility.
Potential for infringement risks:
Given its scope, companies developing similar compounds or formulations must evaluate patent infringement risks, especially if they target the same disease indication or use similar delivery systems.
Critical assessment of the patent's strengths and weaknesses
| Aspect |
Evaluation |
| Novelty |
The patent claims are sufficiently distinct from prior art, especially due to specific formulation parameters and treatment methods. |
| Non-obviousness |
Demonstrates an inventive step through specific combinations and delivery techniques, although some claims are narrowly drafted. |
| Claim breadth |
Some claims are broad but were subject to narrowing amendments during prosecution, limiting market exclusivity. |
| Patent family coverage |
Strategic filings across jurisdictions enhance enforceability but increase portfolio complexity. |
| Vulnerability |
Claims could be challenged or circumvented through alternative active compounds or different delivery methods, especially given prior art disclosures in related fields. |
Implications for R&D and investment decisions
- Patent provides a defensible position in the specified indication, offering potential exclusivity until at least 2034, considering 20-year term from priority.
- Narrow claims require careful avoidance analysis for competitors; broad claims could strengthen market position.
- The patent landscape suggests active patenting in the field, with overlapping rights requiring diligent freedom-to-operate analysis.
- Companies should consider licensing or cross-licensing to mitigate infringement risks.
Key Takeaways
- US 10,130,681 covers specific formulations and methods with patent rights enforceable until around 2034.
- The patent's narrow scope limits broad market exclusivity but secures a strategic niche.
- Overlapping patents, derivatives, and formulation patents threaten to dilute the patent's enforceability.
- Patent prosecution history reveals efforts to distinguish claims from prior art but indicates areas vulnerable to design-around strategies.
- Firms developing similar compounds must thoroughly perform patent landscape analyses and freedom-to-operate assessments.
FAQs
-
What is the primary novelty of US Patent 10,130,681?
It claims a specific pharmaceutical formulation and method of administration that offers pharmacokinetic or therapeutic advantages over prior art.
-
How broad are the patent’s claims?
The claims are narrow, focusing on particular formulations and methods, which limits their market breadth but enhances defensibility.
-
Could competitors circumvent this patent easily?
Yes, by developing alternative active compounds or different delivery mechanisms outside the scope of the claims.
-
What is the patent’s expiry date?
Expected around 2034, assuming maintenance fees are paid and no patent term adjustments or extensions are applied.
-
How strategically important is this patent in the broader landscape?
It provides a strong position within its niche but is part of a complex portfolio requiring comprehensive freedom-to-operate evaluations.
References
[1] United States Patent and Trademark Office. (2018). US Patent 10,130,681. Retrieved from USPTO database.
[2] European Patent Office. (n.d.). Related patent filings. Retrieved from Espacenet.
[3] Patent family filings. (2014–2018). Strategic filing timeline.
[4] Patent prosecution history and amendments. (2018). Retrieved from USPTO.
